Innovent Biologics (Suzhou) Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Innovent Biologics (Suzhou) Co. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Innovent Biologics (Suzhou) Co.: 7 sponsored US clinical trials, 2 recruiting.
Innovent Biologics (Suzhou) Co. sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Locally Advanced Unresectable or Metastatic Solid Tumors, with 1 trials.
Upper-quartile sponsor footprint
Innovent Biologics (Suzhou) Co. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05458219
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
NCT05162365
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
NCT04338659
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
NCT03763149
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
NCT03748134
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
NCT03568539
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 1 |
What is open in the Innovent Biologics (Suzhou) Co. pipeline
2 recruiting of 7 indexed (29% open); 4 completed (57%).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Locally Advanced Unresectable or Metastatic Solid Tumors (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Innovent Biologics (Suzhou) Co.: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Innovent Biologics (Suzhou) Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Innovent Biologics (Suzhou) Co. page
7 registered trials is a research-attention snapshot, not an endorsement of Innovent Biologics (Suzhou) Co. or any single study.
- 2 of Innovent Biologics (Suzhou) Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Locally Advanced Unresectable or Metastatic Solid Tumors is the condition Innovent Biologics (Suzhou) Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Locally Advanced Unresectable or Metastatic Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Innovent Biologics (Suzhou) Co. pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.